BiomX provides pipeline update: BX004 Ph2b results in Q3 2025, BX211 Ph2 results in Q1 2025

BiomX Inc.

BX004 for CF: Phase 2b topline results expected Q3 2025 (60 patients, 2:1 randomized).
BX211 for DFO: Phase 2 topline results expected Q1 2025 (week 26) and Q1 2026 (week 52).
Cash and cash equivalents $32.7M as of June 30, 2024.
Presentation highlights: 14.3% of BX004 patients converted to PsA-negative sputum in Ph1b/2a Part 2.
Peer phage therapy momentum cited: >100 compassionate use cases with 77% clinical improvement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.